Cytokinetics, Incorporated (CYTK) Q1 2015 Earnings Results

Cytokinetics Misses on EPS — Stock Down 6.12%

Cytokinetics' earnings report showed a significant miss on EPS, which likely contributed to the 6.12% drop in stock price. Investors may be concerned about the lack of revenue figures and forward guidance, indicating uncertainty about the company's financial health moving forward. The focus on ongoing clinical trials suggests that management is prioritizing long-term growth over short-term financial performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.23	N/A	-187.50%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding the current financial outlook. They emphasized the importance of their research efforts but did not provide specific guidance.

Management did not provide specific revenue guidance for the upcoming quarters.

The company is focusing on its ongoing clinical trials and research initiatives.

Cytokinetics Misses on EPS — Stock Down 6.12%

Key numbers

Management commentary

Cytokinetics, Incorporated

More earnings this week

Cytokinetics Misses on EPS — Stock Down 6.12%

Key numbers

Management commentary